Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus, Clinical Infectious Diseases, vol.34, issue.1, pp.7-14, 2002. ,
DOI : 10.1086/323335
Epidemiology of invasive fungal infection, International Journal of Antimicrobial Agents, vol.32, pp.103-112, 2008. ,
DOI : 10.1016/S0924-8579(08)70009-8
Defining invasive fungal infections in neutropenic or stem cell transplant patients, Journal of Antimicrobial Chemotherapy, vol.56, issue.suppl 1, pp.12-18, 2005. ,
DOI : 10.1093/jac/dki219
Immunopathogenesis of recurrent vulvovaginal candidiasis, Clin Microbiol Rev, vol.9, issue.3, pp.335-383, 1996. ,
Recurrent vulvovaginal candidiasis, Mol Med, vol.103, issue.2, pp.165-173, 2006. ,
Pathogenesis and Treatment of Recurrent Vulvovaginal Candidiasis, Clinical Infectious Diseases, vol.14, issue.Supplement 1, pp.148-53, 1992. ,
DOI : 10.1093/clinids/14.Supplement_1.S148
Pathogenesis of recurrent vulvovaginal candidiasis, Current Infectious Disease Reports, vol.162, issue.6, pp.514-523, 2002. ,
DOI : 10.1007/s11908-002-0038-7
Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.131, issue.2, pp.198-202, 2007. ,
DOI : 10.1016/j.ejogrb.2006.03.009
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity, Infect Immun, vol.63, issue.2, pp.547-53, 1995. ,
???Specific Systemic Cell???Mediated Immune Reactivities in Human Immunodeficiency Virus???Positive Persons with Mucosal Candidiasis, The Journal of Infectious Diseases, vol.183, issue.2, pp.277-85, 2001. ,
DOI : 10.1086/317944
Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis, Medical Mycology, vol.34, issue.5, pp.337-346, 1996. ,
DOI : 10.1080/02681219680000571
Management of Patients with Recurrent Vulvovaginal Candidiasis, Drugs, vol.126, issue.11, pp.1059-66, 2003. ,
DOI : 10.2165/00003495-200363110-00002
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis, New England Journal of Medicine, vol.351, issue.9, pp.876-83, 2004. ,
DOI : 10.1056/NEJMoa033114
The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models, Int Rev Immunol, vol.21, issue.6, pp.515-563, 2002. ,
Immunity in vaginal candidiasis, Curr Opin Infect Dis, vol.18, issue.2, pp.107-118, 2005. ,
Analysis of vaginal cell populations during experimental vaginal candidiasis, Infect Immun, vol.67, issue.6, pp.3135-3175, 1999. ,
Relation between Recurrent Vulvovaginal Candidiasis, Vaginal Concentrations of Mannose-Binding Lectin, and a Mannose-Binding Lectin Gene Polymorphism in Latvian Women, Clinical Infectious Diseases, vol.37, issue.5, pp.733-740, 2003. ,
DOI : 10.1086/377234
Frequency of Interleukin-4 (IL-4) -589 Gene Polymorphism and Vaginal Concentrations of IL-4, Nitric Oxide, and Mannose-Binding Lectin in Women with Recurrent Vulvovaginal Candidiasis, Clinical Infectious Diseases, vol.40, issue.9, pp.1258-62, 2005. ,
DOI : 10.1086/429246
Association of Recurrent Vaginal Candidiasis and Secretory ABO and Lewis Phenotype, The Journal of Infectious Diseases, vol.176, issue.3, pp.828-858, 1997. ,
DOI : 10.1086/517314
History and update on host defense against vaginal candidiasis, Am J Reprod Immunol, vol.57, issue.1, pp.2-12, 2007. ,
Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection, Infect Immun, vol.61, issue.4, pp.1500-1508, 1993. ,
Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats, Infect Immun, vol.65, issue.8, pp.3399-405, 1997. ,
Inhibit Fungus Adherence to Vaginal Epithelium and Protect against Experimental Vaginal Candidiasis, The Journal of Infectious Diseases, vol.195, issue.1, pp.149-57, 2007. ,
DOI : 10.1086/509891
URL : https://hal.archives-ouvertes.fr/hal-00464705
Evidence for a Role for Secreted Aspartate Proteinase of Candida albicans in Vulvovaginal Candidiasis, Journal of Infectious Diseases, vol.161, issue.6, pp.1276-83, 1990. ,
DOI : 10.1093/infdis/161.6.1276
Anticandidal Immunity and Vaginitis: Novel Opportunities for Immune Intervention, Infection and Immunity, vol.75, issue.10, pp.4675-86, 2007. ,
DOI : 10.1128/IAI.00083-07
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2044548
Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine, Expert Review of Vaccines, vol.5, issue.6, pp.859-67, 2006. ,
DOI : 10.1586/14760584.5.6.859
Intravaginal and Intranasal Immunizations Are Equally Effective in Inducing Vaginal Antibodies and Conferring Protection against Vaginal Candidiasis, Infection and Immunity, vol.70, issue.5, pp.2725-2734, 2002. ,
DOI : 10.1128/IAI.70.5.2725-2729.2002
A Monoclonal Antibody Directed against a Candida albicans Cell Wall Mannoprotein Exerts Three Anti-C. albicans Activities, Infection and Immunity, vol.71, issue.9, pp.5273-5282, 2003. ,
DOI : 10.1128/IAI.71.9.5273-5279.2003
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC187351
Human natural yeast killer toxin-like candidacidal antibodies, J Immunol, vol.156, issue.5, pp.1880-1885, 1996. ,
Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies, J Immunol, vol.152, issue.6, pp.3175-82, 1994. ,
Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis, Infection and Immunity, vol.71, issue.11, pp.6205-6217, 2003. ,
DOI : 10.1128/IAI.71.11.6205-6212.2003
Immune Cell-Mediated Protection against Vaginal Candidiasis: Evidence for a Major Role of Vaginal CD4+ T Cells and Possible Participation of Other Local Lymphocyte Effectors, Infection and Immunity, vol.70, issue.9, pp.4791-4798, 2002. ,
DOI : 10.1128/IAI.70.9.4791-4797.2002
A novel glyco-conjugate vaccine against fungal pathogens, The Journal of Experimental Medicine, vol.14, issue.5, pp.597-606, 2005. ,
DOI : 10.1099/00222615-27-4-233
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212864
Local Anticandidal Immune Responses in a Rat Model of Vaginal Infection by and Protection against Candida albicans, Infection and Immunity, vol.68, issue.6, pp.3297-304, 2000. ,
DOI : 10.1128/IAI.68.6.3297-3304.2000
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis, Infect Immun, vol.61, issue.5, pp.1990-1995, 1993. ,
Utility of the oestrogen-dependent vaginal candidosis murine model in evaluating the efficacy of various therapies against vaginal Candida albicans infection, Mycoses, vol.116, issue.2, pp.104-112, 2006. ,
DOI : 10.1046/j.1365-2249.2003.02032.x
A Multifunctional, Synthetic Gaussia princeps Luciferase Reporter for Live Imaging of Candida albicans Infections, Infection and Immunity, vol.77, issue.11, pp.4847-58, 2009. ,
DOI : 10.1128/IAI.00223-09
Protection by Anti-??-Glucan Antibodies Is Associated with Restricted ??-1,3 Glucan Binding Specificity and Inhibition of Fungal Growth and Adherence, PLoS ONE, vol.64, issue.7, p.5392, 2009. ,
DOI : 10.1371/journal.pone.0005392.s002
The GPI-modified proteins Pga59 and Pga62 of Candida albicans are required for cell wall integrity, Microbiology, vol.155, issue.6, pp.2004-2024, 2009. ,
DOI : 10.1099/mic.0.028902-0
Codon-Optimized Gaussia Luciferase cDNA for Mammalian Gene Expression in Culture and in Vivo, Molecular Therapy, vol.11, issue.3, pp.435-478, 2005. ,
DOI : 10.1016/j.ymthe.2004.10.016
hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis, Medical Mycology, vol.46, issue.5, pp.411-431, 2008. ,
DOI : 10.1080/13693780701883508
Local production of chemokines during experimental vaginal candidiasis, Infect Immun, vol.67, issue.11, pp.5820-5826, 1999. ,
Growth inhibition of Candida albicans by vaginal cells from na??ve mice, Medical Mycology, vol.37, issue.4, pp.251-260, 1999. ,
DOI : 10.1046/j.1365-280X.1999.00228.x
Candida-Specific Antibodies during Experimental Vaginal Candidiasis in Mice, Infection and Immunity, vol.70, issue.10, pp.5790-5799, 2002. ,
DOI : 10.1128/IAI.70.10.5790-5799.2002
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC128320
Phenotypic and Functional Characterization of Vaginal Dendritic Cells in a Rat Model of Candida albicans Vaginitis, Infection and Immunity, vol.74, issue.7, pp.4282-94, 2006. ,
DOI : 10.1128/IAI.01714-05
Candida albicans double-stranded DNA can participate in the host defense against disseminated candidiasis, Microbes and Infection, vol.7, issue.2, pp.178-86, 2005. ,
DOI : 10.1016/j.micinf.2004.10.011
The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins., Journal of Bacteriology, vol.178, issue.18, pp.5353-60, 1996. ,
DOI : 10.1128/jb.178.18.5353-5360.1996
Candida albicans ALS3 and insights into the nature of the ALS gene family, Current Genetics, vol.33, issue.6, pp.451-460, 1998. ,
DOI : 10.1007/s002940050359
Als3 Is a Candida albicans Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells, PLoS Biology, vol.2, issue.3, p.64, 2007. ,
DOI : 10.1371/journal.pbio.0050064.sg003
URL : http://doi.org/10.1371/journal.pbio.0050064
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection, Expert Rev Vaccines, vol.6, issue.5, pp.699-710, 2007. ,
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels, Proceedings of the National Academy of Sciences, vol.21, issue.1, pp.3877-82, 2009. ,
DOI : 10.1146/annurev.immunol.21.120601.141142
MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine, Infect Immun, vol.65, issue.5, pp.1710-1715, 1997. ,